Shareholders see through Protagonist's spin on trial failure

27 April 2022
protagonist_therapeutics_large-1-

The stock market provided a telling assessment of Protagonist Therapeutics’ (Nasdaq: PTGX) presentation of its top-line results from the Phase II IDEAL study evaluating PN-943 in ulcerative colitis (UC).

Shares in the Californian company were 50% lower after trading on Tuesday as markets digested the fact that the 450mg twice-daily dose did not meet the prespecified primary endpoint.

"We believe the results of the IDEAL study may be paradigm shifting"PN-943 is an oral, gut-restricted, alpha-4-beta-7-integrin antagonist. In the trial, 159 patients with moderate-to-severe active UC were randomized to either twice daily with 450 mg or 150 mg PN-943, or placebo, for 12 weeks and analyzed for outcome measures.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Biotechnology